Posts Tagged Brexit
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »
As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.
This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »
In screenwriting the three-act structure progresses from setup to confrontation to resolution, with the first act used for establishing the main characters.
It’s a device for fiction of course, but much of this year feels like just that. In fact, looking back on the last 12 months, 2016 also feels like a setup for events yet to come. Read the rest of this entry »
How confident are you in your country’s healthcare system? That was the central issue for this month’s PME cover feature, which focused on a global study of healthcare perceptions and offered some useful insights into how people think and feel when faced with healthcare decisions.
We also looked at the global scourge that is the problem of counterfeit medicines and hear what the industry is doing to help tackle the problem. Read the rest of this entry »